 TEL AVIV, Israel, April 14, 2021 GLOBE NEWSWIRE -- InspireMD, Inc. NYSE American: NSPR, NSPR.WS, NSPR.WSB, developer of the CGuardTM Embolic Prevention System EPS for the prevention of stroke caused by the treatment of Carotid Artery Disease CAD, today announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021. Beginning on April 27, 2021, the Companys common stock will trade on the NYSE American on a split adjusted basis. 